N-glycolylneuraminic acid-containing GM3 ganglioside (Neu5Gc-GM3) (Neu5Gc-GM3)

N-glycolylneuraminic acid-containing GM3 ganglioside (Neu5Gc-GM3) is a tumor-associated carbohydrate antigen (TACA) characterized by the presence of N-glycolylneuraminic acid (Neu5Gc), a sialic acid variant that humans cannot synthesize due to an evolutionary inactivation of the CMP-Neu5Ac hydroxylase (CMAH) gene [1, 3]. In malignant cells, Neu5Gc-GM3 is aberrantly expressed, often acquired through the metabolic incorporation of dietary Neu5Gc or upregulated under hypoxic conditions within the tumor microenvironment [6, 13]. This molecule plays a critical role in cancer progression by modulating growth factor signaling, such as the epidermal growth factor receptor (EGFR) pathway, and by inducing immunosuppression when shed into the extracellular space [1, 7]. Because it is virtually absent in normal human tissues, Neu5Gc-GM3 serves as a highly specific neoantigen for cancer immunotherapy [3, 5]. Therapeutic strategies targeting this ganglioside include monoclonal antibodies like 14F7 and anti-idiotype vaccines such as Racotumomab, which stimulate the immune system to recognize and eliminate Neu5Gc-GM3-positive tumor cells [2, 4]. Clinical studies have demonstrated that the presence of Neu5Gc-GM3 correlates with poor prognosis in several cancers, including non-small cell lung cancer and breast cancer [12]. The unique metabolic origin of this antigen provides a distinct advantage for targeted therapies, as it minimizes the risk of off-target effects on healthy human cells [5, 15].

Other names

N-glycolyl-GM3Neu5GcGM3NGcGM3N-glycolyl-monosialodihexosylgangliosideHanganutziu-Deicher antigen

Immunotherapy targeting tumor-associated carbohydrate antigens; anti-idiotype vaccine induction of humoral and cellular immune responses; monoclonal antibody-mediated cytotoxicity (ADCC/CDC) and direct cell death induction.